<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971551</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK013</org_study_id>
    <nct_id>NCT04971551</nct_id>
  </id_info>
  <brief_title>A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.</brief_title>
  <official_title>A Phase 2 ,Safety and Efficacy Study of Jaktinib Hydrochloride Tablets for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an single-arm, Phase II multi-center study. The purpose of this study is to assess&#xD;
      the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute&#xD;
      graft-versus-host disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as the percentage of participants demonstrating a complete response (CR), or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first day of Jaktinib treatment to death due to any cause，up to 24 months</time_frame>
    <description>Defined as the time from the first day of Jaktinib treatment to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>From the first day of Jaktinib treatment to 28 days after end of treatment, up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Jaktinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants began oral administration of Jaktinib at 75mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 100mg BID Or continue 75mg BID treatment .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Hydrochloride Tablets</intervention_name>
    <description>Oral on an empty stomach</description>
    <arm_group_label>Jaktinib treatment</arm_group_label>
    <other_name>Jaktinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT)&#xD;
             from any donor source using bone marrow, peripheral blood stem cells, or cord blood&#xD;
             for hematologic malignancies. Recipients of nonmyeloablative and myeloablative&#xD;
             conditioning regimens are eligible.&#xD;
&#xD;
          -  Clinically suspected Grades II to IV acute GVHD according to NCCN guidelines 2020&#xD;
             V2.0, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD&#xD;
             prophylactic program.&#xD;
&#xD;
          -  Subjects with steroid-refractory acute GVHD, defined as any of the following:&#xD;
&#xD;
        Subjects with progressive GVHD (ie, increase in stage in any organ system or any new organ&#xD;
        involvement) after 3-5 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day&#xD;
        (or equivalent) ± Calcineurin inhibitors（CNI）；Subjects with GVHD that has not improved (ie,&#xD;
        decrease in stage in at least 1 involved organ system) after 5-7 days of primary treatment&#xD;
        with methylprednisolone ≥ 2 mg/kg per day (or equivalent) ± Calcineurin&#xD;
        inhibitors（CNI）；Subjects who Corticosteroid dependence（ie, begin corticosteroids at 2.0&#xD;
        mg/kg per day, demonstrate response, but progress before decrease from the initial starting&#xD;
        dose of corticosteroids is achieved）.&#xD;
&#xD;
          -  ECOG: 0-2；&#xD;
&#xD;
          -  Life expectancy &gt; 4 weeks；&#xD;
&#xD;
          -  Ability for oral drug intake；&#xD;
&#xD;
          -  Willingness to comply with all study visits and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received more than 2 allo-HSCT.&#xD;
&#xD;
          -  Acute GvHD occurring after non-scheduled donor leukocyte infusion (DLI) administered.&#xD;
&#xD;
          -  Has received more than 1 systemic treatment in addition to corticosteroids for acute&#xD;
             GVHD.&#xD;
&#xD;
          -  Presence of an active uncontrolled infection.&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 ULN or creatinine clearance &lt; 30 mL/min calculated by&#xD;
             Cockroft-Gault equation.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to any of the study medications,&#xD;
             excipients, or similar compounds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongping Song, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Tumor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Song, PhD</last_name>
    <phone>+86-0371-65587320</phone>
    <email>songyongping001@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongping Song, PhD</last_name>
      <phone>+86-0371-65587320</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

